A crucial debate is unfolding in British Columbia, one that could have a significant impact on the health and well-being of infants across the province. The issue? Ensuring equal access to a potentially life-saving immunization for respiratory syncytial virus (RSV).
RSV is a common virus that usually causes mild cold-like symptoms, but it can lead to severe illness, especially in vulnerable groups like newborns and older adults. A recent study from the University of British Columbia's Faculty of Medicine revealed a startling statistic: babies under six months old account for almost 45% of all RSV-related hospital admissions in Canada, with the total annual costs amounting to nearly $32.5 million.
And here's where it gets controversial: while an infant immunization for RSV is now available across Canada, most parents in British Columbia still have to pay out of pocket for it, and at a substantial cost. Nirsevimab, the RSV infant immunization, is publicly funded in most provinces, but not in B.C.
Dr. Patrick Hemmons, a family physician from northern B.C., knows this struggle all too well. Last year, he had to travel to Seattle to purchase a dose of nirsevimab for his preterm daughter. "It was not easy having to travel to a different country essentially to get medication that should be widely available in Canada," he said. "This medication is extremely effective at preventing RSV, which is a game changer."
But Dr. Hemmons and numerous other parents and doctors aren't just advocating for the shot to be available to all infants; they're calling for it to be free. They believe that every infant, regardless of their family's financial situation, should have equal access to this potentially life-saving immunization.
"There is a huge risk that if your baby catches RSV, they likely will be hospitalized because their body can't handle it at that age," said Katrina Bellavance, a mother from Calgary whose youngest daughter, Maxine, was hospitalized for four days when she was nearly eight weeks old. Bellavance's daughter caught RSV in February 2023, and she wishes the immunization had been an option for her at the time.
"To have the antibody treatment available, especially for premature babies, could keep a lot of babies out of the hospital and save a lot of families a really stressful experience," she added. "It doesn't make sense to me that some provincial governments aren't willing to provide that."
In 2024, the National Advisory Committee on Immunization (NACI) recommended prioritizing coverage for higher-risk infants due to nirsevimab's high price, which was $952 at the time. However, the committee also recommended working towards a universal RSV immunization program for all infants.
The decision to cover the costs of medications ultimately rests with the provinces. The B.C. Ministry of Health reviews eligibility criteria for immunization coverage annually, and for the 2025-26 respiratory illness season, 4,000 doses of nirsevimab are available for high-risk infants. Children who don't meet the criteria can still obtain the antibody privately, but the availability of products for private purchase is at the manufacturer's discretion.
Dr. Katharine Smart, a pediatrician and former president of the Canadian Medical Association, believes coverage eligibility could change. "Given the pressures on our healthcare system and the cost of RSV illness even in babies without risk factors, I think we may see those provinces realize it's a better economic decision to offer nirsevimab for all infants," she said.
Dr. Smart also highlighted the challenge of limited information dissemination when a treatment isn't covered. "We need to be talking about it, making sure families know it's available, but equally important is making it accessible to all babies," she added.
This debate raises important questions: Should access to potentially life-saving immunizations be determined by a family's financial means? Is it time for British Columbia to prioritize the health of its youngest residents and implement a universal RSV immunization program? We'd love to hear your thoughts in the comments below!
